Received Aug 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 1 | — | — |
diabetes; lung cancer; sarcoid of the lung; COVID; COVID; This is a spontaneous report received from a Consumer or other non HCP. A male patient received BNT162b2 omicron (kp.2) (COMIRNATY (2024-2025 FORMULA)), in 2025 as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 2025, outcome "unknown" and all described as "COVID"; LUNG NEOPLASM MALIGNANT (medically significant) with onset 2025, outcome "unknown", described as "lung cancer"; PULMONARY SARCOIDOSIS (medically significant) with onset 2025, outcome "unknown", described as "sarcoid of the lung"; DIABETES MELLITUS (medically significant), outcome "unknown", described as "diabetes". Clinical course: Patient recently fell Ill to COVID, and was informed he was able to get Paxlovid. Much to his surprise of the cost of this medicine (stated as ridiculous). Patient and his wife did get the Pfizer shot at the start of year (2025). Patient is also dealing with diabetes, sarcoid of the lung (an autoimmune disease) and recently found out to have lung cancer. The information on the batch/lot number for BNT162b2 omicron (kp.2) will be requested and submitted if and when received.